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ancouver and Montreal, Canada
OBJECTIVES The purpose of this study was to determine if statins (hydroxymethylglutaryl CoA reductase
inhibitors [HMG-CoA]), angiotensin-converting enzyme (ACE) inhibitors, and angiotensin
receptor blockers (ARBs) reduce cardiovascular (CV) events and pulmonary morbidity in
chronic obstructive pulmonary disease (COPD) patients.
BACKGROUND Few current COPD therapies alter prognosis. Although statins, ACE inhibitors, and ARBs
improve outcomes in CV populations, their benefits in COPD patients both with and
without concomitant heart disease has not previously been studied.
METHODS A time-matched nested case-control study of two population-based retrospective cohorts was
undertaken: 1) COPD patients having undergone coronary revascularization (high CV risk
cohort); and 2) COPD patients without previous myocardial infarction (MI) and newly
treated with nonsteroidal anti-inflammatory drugs (low CV risk cohort). Prespecified
outcomes were COPD hospitalization, MI, and total mortality.
RESULTS These drugs reduced both CV and pulmonary outcomes, with the largest benefits occurring
with the combination of statins and either ACE inhibitors or ARBs. This combination was
associated with a reduction in COPD hospitalization (risk ratio [RR] 0.66, 95% confidence
interval [CI] 0.51 to 0.85) and total mortality (RR 0.42, 95% CI 0.33 to 0.52) not only in the
high CV risk cohort but also in the low CV risk cohort (RR 0.77, 95% CI 0.67 to 0.87, and
RR 0.36, 95% CI 0.28 to 0.45, respectively). The combination also reduced MI in the high
CV risk cohort (RR 0.39, 95% CI 0.31 to 0.49). Benefits were similar when steroid users were
included.
CONCLUSIONS These agents may have dual cardiopulmonary protective properties, thereby substantially
altering prognosis of patients with COPD. These findings need confirmation in randomized
clinical trials. (J Am Coll Cardiol 2006;47:2554–60) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.039Cardiology Foundation
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phronic obstructive pulmonary disease (COPD) is in-
reasing in prevalence, leading to escalating hospitaliza-
ion and mortality risks. Apart from smoking cessation in
ll patient groups and oxygen in severely affected patients,
here is controversy as to whether therapies used in
outine practice modify outcome (1–3). Cardiovascular
CV) events are increasingly being recognized as a major
ause of death in patients with diverse forms of lung
isease (4 –10). We hypothesized that medications cur-
ently associated with CV risk reduction might have a
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Manuscript received August 15, 2005; revised manuscript received March 21, 2006,
ccepted April 4, 2006.ubstantial impact on the clinical outcome of COPD
atients by at least reducing the CV component of
dverse morbidity and mortality in these patients. In
ddition, we hypothesized that statins (hydroxymethyl-
lutaryl CoA reductase inhibitors [HMG-CoA]) and
ngiotensin-converting enzyme (ACE) inhibitors or an-
iotensin receptor blockers (ARBs), through pleiotropic
echanisms, might also modify outcomes directly attrib-
ted to lung disease itself (11). The latter conjecture is
ased on mechanistic studies showing the potential
mportance of these drugs in mitigating diverse forms of
ung injury (12–24). Accordingly, we used population
atabases to explore the impact of these drugs on the
utcome of patients with COPD with respect to both
ulmonary and CV events as well as to overall mortality.
he purpose of this study was to determine whether there
s evidence suggesting dual cardiopulmonary protective
roperties of these agents and to provide a rationale for
ndertaking more definitive randomized clinical trials.
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sing the Quebec Linked Databases, we conducted a
etrospective cohort study which was analyzed using a
ime-matched nested case-control approach to assess the
ssociation between CV drug use (statins, ACE inhibitors,
nd ARBs) and the risk of hospitalization secondary to
OPD, myocardial infarction (MI), and death. These
dministrative databases have been developed for the uni-
ersal health care programs for Quebec citizens. They
apture all physician visits, procedures, hospitalizations, and
utpatient prescription drugs (quantity, strength, dosage,
nd date of dispensing). The hospital database captures
nformation on all patient demographics, admission and
ischarge dates, procedures, and up to 15 secondary diag-
oses. These databases have been previously validated and
xtensively used in research (25,26). A nested case-control
pproach was used because the whole cohort was too large
o analyze using a survival analysis model with time-dependent
ovariates (exposure to the medications of interest).
ohort entry. We tested our hypothesis among two dis-
inct COPD cohorts, because the magnitude of the benefit
or statins, ACE inhibitors, and ARBs may differ among
hose with different CV risk profiles: 1) a cohort of
evascularized patients with relatively high CV risk profile;
nd 2) a general population cohort of nonsteroidal anti-
nflammatory drug (NSAID) users without previous MI.
The source population for the first cohort consisted of
lderly (65 years or older) revascularized (percutaneous
oronary angioplasty and/or bypass grafting) patients (25).
n brief, patients with the first revascularization procedure
uring the period April 1, 1995, to December 31, 2000,
ere followed until December 31, 2002. Patients may have
ad previous revascularization procedures before April 1,
995. Patients were excluded from the cohort if they were
65 years of age at the time of their revascularization
rocedure, were non-Quebec residents, or died in the
ospital during their initial revascularization. (25).
The source population for the second cohort with a lower
V risk profile was also analyzed and consisted of a random
ample of residents of Quebec (65 years or older) who
eceived a prescription for an NSAID between January 1,
999, and June 30, 2002 (26), and again were followed until
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ARB  angiotensin receptor blocker
CI  confidence interval
COPD  chronic obstructive pulmonary disease
CV  cardiovascular
HMG-CoA  hydroxymethylglutaryl CoA reductase
inhibitors
MI  myocardial infarction
NSAID  nonsteroidal anti-inflammatory drug
RR  risk ratioecember 31, 2002. This second cohort specifically ex- fluded any patient with an MI in the five years preceding
ohort entry.
From each of these two source populations we identified
ubcohorts of COPD subjects who were prescribed at least
hree prescriptions on two different dates within the pre-
eding year for a beta2-agonist, inhaled anticholinergic, or
heophylline (27). The date of the third prescription was
hosen as the date of entry into each of the COPD study
ohorts. Those who had used at least one prescription of an
nhaled steroid, nasal steroid, and other drugs including
edocromil, ketotifen, and cromoglycate during the year
receding cohort entry were excluded to avoid inclusion of
ubjects who had a primary diagnosis of asthma. However,
e also examined COPD cohorts allowing those who used
ral or inhaled steroids but not nasal steroids, because the
atter group most likely represented patients with allergic
onditions. This analysis is important, because there is
ontroversy as to the impact of steroid use on outcome of
OPD patients (3).
Members of both COPD cohorts were followed to: 1) the
rst occurrence of our predefined study end points (hospi-
alization for COPD, MI, or death); 2) the emigration from
he province; or 3) the end of study period. All hospitaliza-
ions secondary to COPD (ICD-9 codes 490 to 492 and
96) as well as hospital admissions due to acute MI (ICD-9
ode 410) were identified using the primary discharge
iagnosis code. The date of first hospitalization for COPD
r MI was designated as the index date. The analysis of
hese end points employed a nested case-control method-
logy. The advantages of this analytical technique in assess-
ng CV outcomes have been previously described (28).
asically, for each case of each end point, a risk set of all
otential controls consisting of all cohort members with the
ame age (1 year) and year of cohort entry as the case and
till at risk of the event was formed. This ensured equal
ollow-up time for cases and controls. From this risk set, 20
ontrols were randomly selected and assigned the diagnosis
ate of the matched case. Statin, ARB, and ACE inhibitor
sers were defined as currently exposed if they received at
east one prescription in the 60 days before the index date.
ast users were those who received the drugs of interest
ore remotely than 60 days. In addition to our interest in
ingle agents, we were interested in the effect of combina-
ion therapy, defined as statin use plus either an ACE
nhibitor or an ARB. Drugs other than statins, ACE
nhibitors, and ARBs were treated as covariates.
tatistical analysis. Using conditional logistic regression,
nadjusted risk ratios (RRs) were computed comparing the
isks in the exposed groups taking statins, ACE inhibitors,
nd/or ARBs to a reference group of those not taking any of
he three drugs. Adjusted RRs were calculated controlling
or potential confounders identified using both the hospi-
alization records and from the pharmaceutical database.
pecifically, we adjusted for the effects of gender, age,
istory of prior hospitalization for MI, congestive heart
ailure, or pneumonia, number of drugs used at entry,
n
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Morbidity/Mortality Reduction in COPD June 20, 2006:2554–60umber of physician visits before entry, use of inhaled
nticholinergics, steroids, and beta2-agonists, theophylline,
eta-blockers, calcium-channel blockers, diuretics, nitrates,
nd diabetes therapies. It should be noted that the databases
o not allow for assessment of COPD severity based on
ung function testing, biochemical severity of dyslipidemia,
moking status/quantity, or severity of hypertension. It
hould also be noted that in the low CV risk cohort, all
atients in both the group exposed to statins, ACE inhib-
tors, and ARBs and the reference group were exposed to
SAIDs, thereby precluding demonstration of any effect of
his class on outcomes. All analyses were done using SAS
ersion 9 (SAS Institute, Cary, North Carolina). Differ-
Table 1. Summary of Number of Cases and C
High- and Low-Risk Cohorts
Cohort End Point
High-risk Hospitalization for COPD
MI
Death
Death or MI
Low-risk Hospitalization for COPD
MI
Death
Death or MI
COPD  chronic obstructive pulmonary disease; MI  my
Table 2. Demographics of Cases and Controls
Patients Not Using Steroids in the Year Prior
Revascularization (High-Risk Cohort)
Age at index date (yrs, mean  SD)
Gender (%)
Female
Male
Hospitalizations in year preceding cohort entry (%)
Prior myocardial infarction
Congestive heart failure
Pneumonia
Co-variate medications in year preceding cohort entr
Calcium channel blockers
Beta-blockers
Diuretics
Nitrates
Anti-diabetic
Inhaled anticholinergics
Inhaled beta2-agonists
Theophylline
In- and out-patient doctor visits in year prior to
cohort entry
Number of unique drugs in year prior to cohort entrAnalysis was performed with respect to end point of hospitalizationces between cases and controls were assessed using t tests
nd chi-square analysis and confirmed using univariate
onditional logistic regression.
ESULTS
able 1 gives a summary of the number of cases and controls
hat were identified for each end point, for both the high-
nd low-risk cohorts, and with respect to whether steroid
se was excluded or included.
Table 2 shows features for cases (n  946) and controls
n  18,774) for the COPD hospitalization end point
dentified from the cohort of patients with both COPD and
ls for Each End Point Examined in the
Steroid
Users
Cases
(n)
Controls
(n)
Excluded 946 18,774
Included 1,028 20,429
Excluded 1,028 20,385
Included 1,111 22,064
Excluded 1,009 20,011
Included 1,092 21,692
Excluded 2,058 40,829
Included 2,226 44,227
Excluded 4,907 98,097
Included 5,344 106,852
Excluded 491 9,820
Included 529 10,580
Excluded 2,219 44,260
Included 2,368 47,240
Excluded 2,710 54,080
Included 2,897 57,820
al infarction.
hronic Obstructive Pulmonary Disease
ohort Entry and Who Had Coronary
Cases
(n  946)
Controls
(n  18,774)
p
Values
72  6 72  6 0.5245
35 34 0.5029
65 66
5.9 7.3 0.1182
3.9 2.9 0.0869
3.0 1.6 0.0018
33.2 36.5 0.0383
17.1 24.0 0.0001
24.7 24.7 0.9967
28.7 33.0 0.0053
14.5 14.6 0.2304
1.3 1.1 0.5885
3.1 3.9 0.1840
0.7 1.0 0.5074
20  25 19  22 0.1012
19  9 16  8 0.0001ontroin C
to C
y (%)
yn for chronic obstructive pulmonary disease.
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June 20, 2006:2554–60 Morbidity/Mortality Reduction in COPDevascularization (high CV risk). Similarly, Table 3 shows
he characteristics of cases (n  4,907) and controls (n 
8,097) for the same end point but identified from the
ohort of patients prescribed NSAIDs (low CV risk),
ndicating 4,907 cases and 98,097 controls. The distribution
f these covariates for cases and controls for all other
utcomes studied were essentially the same.
Table 4 shows the crude unadjusted RRs for the two
OPD cohorts, stratified as to whether steroid users were
ncluded or not. Figures 1 and 2 demonstrate the fully
Table 3. Demographics of Cases and Controls
Patients Not Using Steroids in the Year Prior
Nonsteroidal Anti-Inflammatory Drugs (Low-
Age at index date (yrs, mean  SD)
Gender (%)
Female
Male
Hospitalizations in year preceding cohort entry (%)
Congestive heart failure
Pneumonia
Co-variate medications in year preceding cohort entr
Calcium channel blockers
Beta-blockers
Diuretics
Nitrates
Anti-diabetic
Inhaled anticholinergics
Inhaled beta2-agonists
Theophylline
In- and out-patient doctor visits in year prior to
cohort entry
Number of unique drugs in year prior to cohort entr
Analysis was performed with respect to end-point of hospita
able 4. Unadjusted Risk Ratios and 95% Confidence Intervals i
High-Risk
Steroid Users
Excluded
ospitalization for COPD
ACE inhibitors 1.20 (0.95–1.52)
ARBs 1.51 (1.08–2.11)
Statin drugs 0.88 (0.69–1.12)
Statin and ACE inhibitor or ARB 0.96 (0.75–1.23)
I
ACE inhibitors 0.62 (0.51–0.76)
ARBs 0.63 (0.45–0.89)
Statin drugs 0.44 (0.36–0.54)
Statin and ACE inhibitor or ARB 0.34 (0.27–0.43)
eath
ACE inhibitors 1.44 (1.14–1.81)
ARBs 1.03 (0.71–1.49)
Statin drugs 0.62 (0.48–0.79)
Statin and ACE inhibitor or ARB 0.68 (0.53–0.87)
eath or MI
ACE inhibitors 0.94 (0.81–1.09)
ARBs 0.88 (0.69–1.12)
Statin drugs 0.53 (0.45–0.62)
Statin and ACE inhibitor or ARB 0.49 (0.42–0.58)CE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; CHF  codjusted RRs. In the high-risk cohort (Fig. 1), and irrespec-
ive of whether steroid users are included or not, substantial
isk reduction for hospitalization for COPD was seen with
se of statin (RR 0.72, 95% confidence interval [CI] 0.56 to
.92; p  0.0091) and with the use of statin and ACE
nhibitors or ARBs (RR 0.66, 95% CI 0.51 to 0.85; p 
.0012); when steroid users were included, the respective
esults were RR 0.71, 95% CI 0.56 to 0.90 (p 0.0038) and
R 0.69, 95% CI 0.55 to 0.88 (p  0.0027). Risk ratios
ere reduced for the end point of MI by all three drug
hronic Obstructive Pulmonary Disease
ohort Entry and Who Were Taking
Cohort)
Cases
(n  4,907)
Controls
(n  98,097)
p
Values
77  6 77  6 0.7983
51 58
49 42 0.0001
2.6 2.1 0.0060
3.2 2.6 0.0138
18.0 17.3 0.1832
7.5 9.3 0.0001
19.3 19.0 0.6847
9.1 8.5 0.1214
6.6 6.2 0.3282
0.2 0.3 0.1813
2.1 2.0 0.7075
0.1 0.3 0.0233
5  9 5  19 0.6260
14  7 12  6 0.0001
n for chronic obstructive pulmonary disease.
High- and Low-Risk COPD Cohorts
rt Low-Risk Cohort
Steroid Users
Included
Steroid Users
Excluded
Steroid Users
Included
.18 (0.94–1.48) 1.11 (1.02–1.20) 1.05 (0.97–1.13)
.34 (0.97–1.86) 0.96 (0.86–1.07) 0.96 (0.86–1.06)
.89 (0.71–1.12) 0.84 (0.76–0.93) 0.79 (0.72–0.87)
.04 (0.83–1.31) 1.07 (0.94–1.21) 0.98 (0.87–1.11)
.67 (0.55–0.81) 1.58 (1.21–2.05) 1.62 (1.26–2.09)
.69 (0.51–0.95) 1.40 (1.01–1.96) 1.40 (1.01–1.93)
.44 (0.36–0.54) 0.93 (0.65–1.34) 1.02 (0.73–1.43)
.35 (0.28–0.44) 2.10 (1.52–2.90) 2.00 (1.46–2.75)
.52 (1.21–1.91) 1.04 (0.92–1.18) 0.97 (0.86–1.09)
.04 (0.73–1.49) 0.75 (0.63–0.90) 0.66 (0.55–0.78)
.65 (0.51–0.83) 0.62 (0.51–0.74) 0.56 (0.46–0.66)
.72 (0.56–0.92) 0.58 (0.46–0.73) 0.54 (0.44–0.68)
.92 (0.80–1.07) 1.11 (1.00–1.24) 1.15 (1.03–1.29)
.89 (0.71–1.11) 0.81 (0.69–0.95) 0.87 (0.75–1.01)
.55 (0.47–0.64) 0.69 (0.59–0.81) 0.73 (0.63–0.85)
.50 (0.42–0.58) 0.80 (0.67–0.96) 0.83 (0.69–0.99)in C
to C
Risk
y (%)
yn the
Coho
1
1
0
1
0
0
0
0
1
1
0
0
0
0
0
0ngestive heart failure; MI  myocardial infarction.
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Morbidity/Mortality Reduction in COPD June 20, 2006:2554–60lasses and especially by the combination of statin with
ither ACE inhibitor or ARB (RR 0.39, 95% CI 0.31 to
.49; p  0.0001). Similar reductions were seen when
teroid users were included in the COPD cohort, except
hat the risk reduction for ARBs was not significant. Death
isk ratios were reduced by ARBs (RR 0.63, 95% CI 0.44 to
.89; p  0.0010), statins (RR 0.50, 95% CI 0.40 to 0.62;
 0.0001), and statins with ACE inhibitors or ARBs (RR
.42, 95% CI 0.33 to 0.52; p  0.0001). Virtually identical
esults were seen when steroid users were included. Risk
atios for the combined end point of death or MI were
ignificantly reduced by ACE inhibitors (RR 0.77, 95% CI
.66 to 0.90; p  0.0008), ARBs (RR 0.71, 95% CI 0.56 to
.90; p  0.0054), statins (RR 0.48, 95% CI 0.41 to 0.56;
 0.0001), and the combination of statins with ACE
nhibitors or ARBs (RR 0.39, 95% CI 0.33 to 0.47; p 
.0001). Again, virtually identical results were seen when
teroid users were included.
Figure 2 shows the key results in the low-risk group
nalyses. The main difference between this analysis and the
nalysis in the high-risk groups is a lack of benefit in
revention of MI. The only difference between the inclusion
f steroid users (right panel) and their exclusion in the
ow-risk cohort analysis is in the efficacy of ACE inhibitors
or the reduction of hospitalization for COPD. When
teroid users were excluded, this result was not statistically
igure 1. Fully adjusted risk ratios are plotted for the end points of hospitali
MI), death, and MI or death. Treatments analyzed were angiotensin-conv
hydroxymethylglutaryl CoA reductase inhibitors [HMG-CoA]), and the
opulation of COPD patients with prior revascularization (high risk). Reignificant, whereas when steroid users were included the iesults were statistically significant (RR 0.90, 95% CI 0.83
o 0.98; p  0.0107).
ISCUSSION
his observational study suggests that the cardioprotective
ffects of statins, ACE inhibitors, and ARBs extend also to
OPD patients regardless of their concomitant CV risk
rofile and whether steroid users are included or not in the
nalyses. The risk reductions ranging from 10% to 66% may
ossibly be due to the coexistence of COPD and coronary
isease, coexistence of numerous risk factors for CV disease
ommonly seen in COPD patients (e.g., smoking, obesity,
iabetes, hypertension), and perhaps also because of the
ynergy between CV events and pulmonary inflammation
29–31). In addition, and of special importance, these
gents also seem to affect pulmonary disease itself, as
uggested by reduced hospitalizations for COPD. This is
ossibly due to mitigation of pulmonary injury by statins
nd drugs affecting angiotensin II (12–24). The possibility
hat these classes of drugs have dual cardiopulmonary
rotective properties has not been seriously considered in
iscussions of new therapies for COPD (32).
The strengths of this study include the large cohorts of
OPD patients with various CV risk profiles (Table 1), the
act that they are representative of the general population,
he statistical control of many known confounders, includ-
for chronic obstructive pulmonary disease (COPD), myocardial infarction
enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), statins
bination of statins with ACE inhibitors or ARBs (combination) in the
ncluding steroid users are in the right panel.zation
ertingng control for calendar time bias, other clinical events, and
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June 20, 2006:2554–60 Morbidity/Mortality Reduction in COPDrug usage, the high frequency of events, which allows for
alculation of reasonably precise estimates of risk reduction,
nd, perhaps most important, the relative consistency of
esults in the two cohorts and irrespective of whether steroid
sers were included or not. On the other hand, our analyses
nd conclusions must be considered speculative, because
hey are based on a retrospective cohort analysis rather than
randomized clinical trial. As such, the results may be
usceptible to confounding or channeling bias. For example,
he databases did not allow us to adjust for all known
otential confounders, including severity of COPD, smok-
ng, or severity of known CV risk factors such as dyslipide-
ia. Accordingly, these results are best seen as hypothesis
enerating. However, we believe that the magnitude of
otential benefit provides compelling evidence to justify a
andomized clinical trial, particularly given the dearth of
isease-modifying therapies for the increasing prevalence of
atients with COPD. Because the confidence limits of the
isk reductions seen with statins and the combination of
tatins and ACE inhibitors or ARBs overlap, it would be
articularly important to ensure sufficient power in prospec-
ive trials to determine if synergy truly exists between statins
nd ACE inhibitors or between statins and ARBs. It would
lso be important to determine if COPD patients at lower
isk are truly recalcitrant to reductions in MI, an outcome
hat we did not anticipate, or whether this simply represents
igure 2. Fully adjusted risk ratios are plotted for the end points of hospitali
MI), death, and MI or death. Treatments analyzed were angiotensin-conv
hydroxymethylglutaryl CoA reductase inhibitors [HMG-CoA]), and the
opulation of COPD patients without previous MI and newly treated with
re in the right panel.lack of power in the present study for this outcome.imilarly, the mechanism for reduced total mortality in this
ower-risk cohort requires consideration of end points other
han MI or hospitalization for COPD that might explain
hat effect. Finally, the effects of these agents on other
ulmonary events (e.g., recurrent pneumonia, deterioration
f pulmonary function, and so on) and mechanisms of
ulmonary injury merit further elucidation. Accordingly, we
elieve that these results provide strong impetus for a
aradigm shift in the scientific approach to treatment of
OPD and that properly controlled clinical trials are
arranted to validate these important observations.
eprint requests and correspondence: Dr. G. B. John Mancini,
ancouver Hospital, 3300-950 West 10th Avenue, Vancouver,
ritish Columbia, Canada V5Z 4E3. E-mail: mancini@
nterchange.ubc.ca.
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